Abstract
IntroductionInequities in COVID-19 infection and vaccine uptake among historically marginalised racial and ethnic groups in the USA persist. Individuals with rheumatic conditions, especially those who are immunocompromised, are especially vulnerable to severe infection, with significant racialised inequities in infection outcomes and in vaccine uptake. Structural racism, historical injustices and misinformation engender racial and ethnic inequities in vaccine uptake. The Popular Opinion Lleader (POL) model, a community-based intervention that trains trusted community leaders to disseminate health information to their social network members (eg, friends, family and neighbours), has been shown to reduce stigma and improve care-seeking behaviours.Methods and analysisThis is a community-based cluster randomised controlled trial led by a team of community and academic partners to compare the efficacy of training POLs with rheumatic or musculoskeletal conditions using a curriculum embedded with a racial justice vs a biomedical framework to increase COVID-19 vaccine uptake and reduce vaccine hesitancy. This trial began recruitment in February 2024 in Boston, Massachusetts and Chicago, Illinois, USA. Eligible POLs are English-speaking adults who identify as Black and/or of African descent, have a diagnosis of a rheumatic or musculoskeletal condition and have received >=1 COVID-19 vaccine after 31 August 2022. POLs will be randomised to a 6-module virtual educational training; the COVID-19 and vaccine-related content will be the same for both groups however the framing for arm 1 will be with a racial justice lens and for arm 2, a biomedical preventative care-focused lens. Following the training, POLs will disseminate the information they learned to 12–16 social network members who have not received the most recent COVID-19 vaccine, over 4 weeks. The trial’s primary outcome is social network member COVID-19 vaccine uptake, which will be compared between intervention arms.Ethics and disseminationThis trial has ethical approval in the USA. This has been approved by the Mass General Brigham Institutional Review Board (IRB, 2023P000686), the Northwestern University IRB (STU00219053), the Boston University/Boston Medical Center IRB (H-43857) and the Boston Children’s Hospital IRB (P00045404). Results will be published in a publicly accessible peer-reviewed journal.Trial registration numberNCT05822219.
Funder
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Rheumatology Research Foundation
Reference54 articles.
1. COVID-19 vaccination coverage, by race and ethnicity — national immunization survey adult COVID module, United States, December 2020–November 2021;Kriss;MMWR Morb Mortal Wkly Rep,2020
2. Structural racism, place, and COVID-19: a narrative review describing how we prepare for an endemic COVID-19 future;Estrada;H E,2022
3. Advancing Health Equity: A Guide to Language, Narrative and Concepts,
4. Structural Racism and Health Equity Language Guide, 2023. Available: https://professional.heart.org/-/media/PHD-Files-2/Science-News/s/structural_racism_and_health_equity_language_guide.pdf [Accessed 11 Jan 2024].
5. What to know about the updated COVID-19 vaccine for fall/winter 2023 | johns hopkins | bloomberg school of public health. 2023. Available: https://publichealth.jhu.edu/2023/what-to-know-about-the-updated-covid-19-vaccine-for-fall/winter-2023 [Accessed 15 Sep 2023].